How many organs could you donate and remain alive? How many planet Earths could fit inside the Sun? How high is a giraffe's blood pressure? Why is the sea blue? To find out, Ask The Naked Scientists!
…
continue reading
Contenido proporcionado por PER Spectives and PER® Spectives. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente PER Spectives and PER® Spectives o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !
¡Desconecta con la aplicación Player FM !
S1 Ep7: Part 5 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with Balazs Halmos MD, MS
MP3•Episodio en casa
Manage episode 338150201 series 2987803
Contenido proporcionado por PER Spectives and PER® Spectives. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente PER Spectives and PER® Spectives o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or undergoing late-stage evaluation that target genomic alterations and biomarkers, including EGFR, MET, HER3, NRG1, HER2, TROP2, ROS1, KRAS, NTRK, and RET.
This featured podcast includes interviews with some of the field’s top experts on where we are in terms of testing, safety and efficacy of therapies targeted to the top 10 oncogenic markers in 2022.
This featured podcast includes interviews with some of the field’s top experts on where we are in terms of testing, safety and efficacy of therapies targeted to the top 10 oncogenic markers in 2022.
29 episodios
MP3•Episodio en casa
Manage episode 338150201 series 2987803
Contenido proporcionado por PER Spectives and PER® Spectives. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente PER Spectives and PER® Spectives o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or undergoing late-stage evaluation that target genomic alterations and biomarkers, including EGFR, MET, HER3, NRG1, HER2, TROP2, ROS1, KRAS, NTRK, and RET.
This featured podcast includes interviews with some of the field’s top experts on where we are in terms of testing, safety and efficacy of therapies targeted to the top 10 oncogenic markers in 2022.
This featured podcast includes interviews with some of the field’s top experts on where we are in terms of testing, safety and efficacy of therapies targeted to the top 10 oncogenic markers in 2022.
29 episodios
Todos los episodios
×Bienvenido a Player FM!
Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.